{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-230906","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.209208+00:00","generated_at":"2026-05-17T04:33:24.041911+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"KalVista appoints Bilal Arif as COO and Linea Aspesi as Chief People Officer","bullets":["Bilal Arif appointed COO effective Oct 6, 2025; base salary $520k, annual bonus target 40%, option grant of 100,000 shares.","Linea Aspesi appointed Chief People Officer; also receives inducement option grant of 100,000 shares.","Both options vest over 4 years: 1/4th on 1-year anniversary, then monthly vesting.","Appointments support global launch of EKTERLY for hereditary angioedema.","Arif was EVP at Sarepta Therapeutics; Aspesi was Chief Admin Officer at Editas Medicine."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-230906","json":"https://secwatch.observer/filing/0001193125-25-230906.json","markdown":"https://secwatch.observer/filing/0001193125-25-230906.md","text":"https://secwatch.observer/filing/0001193125-25-230906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525230906/0001193125-25-230906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525230906/d42627d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:33:24.041911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}